Global Respiratory Diagnostics Market Size By Test Type, By Products And Services, By End User, By Geographic Scope And Forecast

Respiratory Diagnostics Market Size And Forecast

Respiratory Diagnostics Market size was valued at USD 4.69 Billion in 2020 and is projected to reachUSD 7.99 Billion by 2028, growing at aCAGR of 6.3% from 2021 to 2028.

Factors such as increasing lung-related diseases and infections, the rise in the geriatric population, and technological developments are leading to growth in the market. On the other hand, risks associated with reimbursements and the rising healthcare cost might hinder the overall market growth. The Global Respiratory Diagnostics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Respiratory Diagnostics Market Definition

Respiratory Diagnostics is one of the most used technologies in the medicinal sector and diagnostic centers. The reason for the market growth is mainly the lifestyle changes in the young population and age-related symptoms and diseases in the geriatric population.

Global Respiratory Diagnostics Market Overview

Factors such as increasing lung-related diseases and infections, the rise in the geriatric population and technological developments are leading to the growth in the market. On the other hand, risks associated with reimbursements and the rising healthcare cost might hinder the overall market growth. The growing number of smokers and consumption of alcohol, along with sedentary lifestyle habits and stressful routines, have resulted in increased incidences of COPD and other severe respiratory conditions, such as lung cancer. Moreover, several technological innovations in respiratory diagnostic testing, counting the use of Artificial Intelligence (AI) and the Internet of Things (IoT) for the diagnosis of COPD and outpatient management, are creating a positive impact on the market growth.

There are certain restraints and challenges faced which will hinder the market growth. Factors such as High price associated with COPD diagnosis and testing, a presence of a large population going undiagnosed and undertreated, Strict regulatory requirements, lack of awareness, and Reimbursement concerns are expected to restrain the growth of the global Respiratory Diagnostics Market.

Global Respiratory Diagnostics Market: Segmentation Analysis

Global Respiratory Diagnostics Market is segmented based on Test Type, Products and Services, End User, And Geography.

Respiratory Diagnostics Market, By Test Type

• Mechanical Tests
• OSA Diagnostic Tests
• Imaging Tests
• Molecular Diagnostic Tests
• Others

Based on Test Type, the market is bifurcated into Mechanical Tests, OSA Diagnostic Tests, Imaging Tests, Molecular Diagnostic Tests, and Others. The OSA Diagnostic Tests segment is projected to account for the largest share of the market. The factors can be attributed to the quick turnaround time of these tests.

Respiratory Diagnostics Market, By Products And Services

• Instruments and Devices
• Assays and Reagents
• Services and Software

Based on Products and Services, the market is bifurcated into Instruments and Devices, Assays and Reagents and Services & Software. The instruments and devices segment is anticipated to account for the largest share in the market. The factors can be attributed to the continuous requirement of diagnostic instruments and devices in point-of-care, laboratories, and home care.

Respiratory Diagnostics Market, By End User

• Hospital/Clinical Laboratories
• Reference Laboratories
• Physician Offices
• Other End Users

Based on End User, the market is bifurcated into Hospital/Clinical Laboratories, Reference Laboratories, Physician Offices and Other End Users. The Hospital/Clinical Laboratories segment is expected to account for the largest share of the global market due to most respiratory disease diagnostics are done in hospitals as they are complex and need technologically advanced products this factor is driving the market for Hospital/Clinical Laboratories.

Respiratory Diagnostics Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, the Global Respiratory Diagnostics Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America. The factors can be attributed to the growing prevalence of respiratory diseases and the increasing geriatric population in the region. Furthermore, the occurrence of an advanced healthcare system and robust distribution channels for respiratory diagnostic products are other factors supporting the growth of this market in North America.

Key Players

• The "Global Respiratory Diagnostics Market" study report will provide a valuable insight with an emphasis on global market including some of the major players such as
• Philips Healthcare, Becton, Dickinson & Company, Abbott Laboratories, Thermo Fisher Scientific Inc., Alere Inc., Bio-Rad Laboratories, Inc., Cosmed, Seegene Inc. and Sdi Diagnostic.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• Product Launches and Product Expansions
• In June 2020, GE Healthcare launched the Thoracic Care Suite that has eight artificial intelligence (AI) algorithms that allow chest X-rays to detect abnormalities, including pneumonia detection, a symptom related to COVID-19. This new product launched by the company during the expansion of COVID-19 has enhanced the credibility of the company in the market.
• On July 2020 BATM, a leading provider of real-time technologies for networking solutions and medical laboratory systems, has announced the launch of three new diagnostic kits to significantly advance the diagnosis of COVID-19 and other respiratory illnesses.
• May 2020, Australian medical technology company, 4DMedical has received clearance from the US Food & Drug Administration to market its XV Technology, a patented four-dimensional lung imaging process that rapidly and automatically analyses any functional lung impairment from a single X-ray. 4DMedical's US operations are based in Woodland Hills, California.
• Acquisition and Mergers
• May 2020, SIME, a Clinical AI company specialising in rapid ICU diagnostics, announced it has entered into an exclusive agreement with an existing strategic investor to commercialise the company's point-of-care products and services in Latin America.